Skip to Content
Search Menu

RNA Expression Profiles May Guide Future Targeted Therapy in Urothelial Cancer

Understanding subtype-specific profiles of urothelial carcinoma could help tailor targeted therapies and identify biomarkers for treatment optimization. At the ESMO 2025 congress, a German study gave new insights into RNA expression of molecular targets across tumor types of urothelial carcinoma.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Related

Katharina Leuchte

ESMO 2025: High-Intensity Interval Training Promotes Immune Responses in mNSCLC Patients

/ Katharina Leuchte
ESMO25Lung cancer Play the Video 05:43

Combination Therapy with Enzalutamide and Radium-223 in mCRPC: Insights from the REASSURE Study

/ Igle Jan de Jong / Jan Andreasen
ESMO25

LBA20: Sacituzumab Govitecan Significantly Prolongs PFS versus Chemotherapy in Advanced Triple-Negative Breast Cancer

/ Jan Andreasen
Breast cancerESMO25NBCN
John Crown

ESMO 2025: Ribociclib + NSAI Reduced the Risk of Invasive and Distant Recurrence of HR+/HER2−Early Breast Cancer

/ John Crown
Breast cancerESMO25NBCN Play the Video 03:24
Charles Geyer

ESMO 2025: Paradigm Shift in Breast Cancer Treatment

/ Charles E Geyer Jr.
Breast cancerESMO25NBCN Play the Video 05:53
Jakob Lauritsen

ESMO 2025: Interesting New Data on the Treatment of Bladder Cancer

/ Jakob Lauritsen
Bladder cancerESMO25 Play the Video 03:47
Hildur Helgadottir

ESMO 2025: Superior Outcomes With Reduced NIVO+IPI Dose in Advanced Melanoma

/ Hildur Helgadottir
ESMO25Melanoma Play the Video 05:27
Katarina Puco

ESMO 2025: Precision Medicine Trial Shows Promise in Rare Cancers

/ Katarina Puco
ESMO25 Play the Video 01:56

ESMO 2025: Advancements to Improve Patient Outcomes and Quality of Life in Immunotherapy

/ Christina Ruhlmann
ESMO25 Play the Video 4:45
Back to top